Document is current
Any future updates will be listed below
-
Authors
Marcucci, G
Biver, E
Body, J J https://orcid.org/0000-0002-9165-1444
Campusano, C https://orcid.org/0000-0001-5483-9301
Cannata-Andía, J
Confavreux, C
de Villiers, T J
Ebeling, P R
Hadji, P https://orcid.org/0000-0003-4787-3151
Kendler, D
El Maghraoui, A
Napoli, N
Veronesi, P
Rizzoli, R https://orcid.org/0000-0002-1537-422X
Brandi, M L https://orcid.org/0000-0002-8741-0592
- License Information
-
More Information
Article History
Received: 6 May 2025
Accepted: 1 December 2025
First Online: 12 January 2026
Declarations
:
: Not applicable.
: E.B. reports advisory and lecture fees from Amgen. A.E. M Abdellah El Maghraoui has received lecture fees from Amgen. C.Ca. has received advisory and lecture fees from FAES farrma, Novartis, Adium, Tecnofarma. J. C.-A. reports advisory board and lecture fees from Mabxience & SPA Farma Ibérica. C. Co. reports congress and lecture fees from Amgen and has received a research grant from Amgen and the 2022 French Amgen Research Award. T. de V. reports advisory and lecture fees from Abbott, Amgen and Cipla Medpro. P. H. has received lecture fees from Amgen, Astellos, Besins, Exeltis, Fresenius, Gedeon Richter, Hexal, Novartis, Pfizer, Stada, Theramex, and UCB. A. E. M. has received lecture fees from Amgen. M.L.B. has received fee for honoraria from Amgen, Ascendis, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, for Grants and/or speaker from Alexion, Amgen, Amolyt, Bruno Farmaceutici, CoGeDi, Echolight, Gedeon Richter, Kyowa Kirin, Monte Rosa Therapeutics, UCB and for Consultant from Aboca, Alexion, Amolyt, Bruno Farmaceutici, Calcilytix, Echolight, Enterabio, Kyowa Kirin, Personal Genomics, and Septerna. J. J. B., P. E., D. K., G.M, N. N. P.V., and R. R. declare no conflict of interest.
